English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Over the past years, there has been an increasing trend in the number of product development partnerships (PDPs), primarily seeking to discover and produce new products in response to the global health threat posed by infectious diseases. This research exploits public and subscription-based databases to examine PDPs’ attributes and their impact on medical innovation in infectious diseases. We find that i) non-private funding is beneficial in the early stages of drug development by PDPs, ii) specific funder and product types are essential for the success of products developed by PDPs, iii) public sector funding is more common in products with lower chances of being approved, and iv) the lower the scientific advances in a sub-disease area are, the lower the likelihood of a product in that area of succeeding.

Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases